465 related articles for article (PubMed ID: 37280670)
1. Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.
Ahmadi SE; Shabannezhad A; Kahrizi A; Akbar A; Safdari SM; Hoseinnezhad T; Zahedi M; Sadeghi S; Mojarrad MG; Safa M
Biomark Res; 2023 Jun; 11(1):60. PubMed ID: 37280670
[TBL] [Abstract][Full Text] [Related]
2. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
3. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor: a neglected role in cancer biology.
Li H; Yu Y; Gao L; Zheng P; Liu X; Chen H
J Thromb Thrombolysis; 2022 Jul; 54(1):97-108. PubMed ID: 35763169
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor as a new target for tumor therapy-killing two birds with one stone: a narrative review.
Li X; Cao D; Zheng X; Wang G; Liu M
Ann Transl Med; 2022 Nov; 10(22):1250. PubMed ID: 36544632
[TBL] [Abstract][Full Text] [Related]
6. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
7. First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using
Loft M; Christensen C; Clausen MM; Carlsen EA; Hansen CP; Kroman N; Langer SW; Høgdall C; Madsen J; Gillings N; Nielsen CH; Klausen TL; Holm S; Loft A; Berthelsen AK; Kjaer A
J Nucl Med; 2022 Dec; 63(12):1871-1879. PubMed ID: 35589407
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor as a novel target for treatment of breast cancer.
Cole M; Bromberg M
Oncologist; 2013; 18(1):14-8. PubMed ID: 23287882
[TBL] [Abstract][Full Text] [Related]
10. Microparticles as Biomarkers of Blood Coagulation in Cancer.
Nomura S; Niki M; Nisizawa T; Tamaki T; Shimizu M
Biomark Cancer; 2015; 7():51-6. PubMed ID: 26462252
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.
López-Pedrera C; Barbarroja N; Dorado G; Siendones E; Velasco F
Leukemia; 2006 Aug; 20(8):1331-40. PubMed ID: 16728982
[TBL] [Abstract][Full Text] [Related]
12. Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.
Theunissen JW; Cai AG; Bhatti MM; Cooper AB; Avery AD; Dorfman R; Guelman S; Levashova Z; Migone TS
Mol Cancer Ther; 2018 Nov; 17(11):2412-2426. PubMed ID: 30126944
[TBL] [Abstract][Full Text] [Related]
13. Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis.
Rondon AMR; Kroone C; Kapteijn MY; Versteeg HH; Buijs JT
Semin Thromb Hemost; 2019 Jun; 45(4):396-412. PubMed ID: 31096312
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
Rak J; Milsom C; May L; Klement P; Yu J
Semin Thromb Hemost; 2006 Feb; 32(1):54-70. PubMed ID: 16479463
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
16. Role of tissue factor in cancer.
Kasthuri RS; Taubman MB; Mackman N
J Clin Oncol; 2009 Oct; 27(29):4834-8. PubMed ID: 19738116
[TBL] [Abstract][Full Text] [Related]
17. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
Rickles FR; Shoji M; Abe K
Int J Hematol; 2001 Feb; 73(2):145-50. PubMed ID: 11372724
[TBL] [Abstract][Full Text] [Related]
18. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
[TBL] [Abstract][Full Text] [Related]
19. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy.
Yu JL; May L; Klement P; Weitz JI; Rak J
Semin Thromb Hemost; 2004 Feb; 30(1):21-30. PubMed ID: 15034795
[TBL] [Abstract][Full Text] [Related]
20. A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy.
Shi W; Yin Y; Wang Y; Zhang B; Tan P; Jiang T; Mei H; Deng J; Wang H; Guo T; Pang Z; Hu Y
Oncotarget; 2017 May; 8(19):32212-32227. PubMed ID: 27793028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
